- Home
- IGA vs ADAP Comparison
IGA vs ADAP Comparison
Compare IGA & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGA
- ADAP
- Stock Information
- Founded
- IGA 2005
- ADAP 2008
- Country
- IGA United States
- ADAP United Kingdom
- Employees
- IGA N/A
- ADAP N/A
- Industry
- IGA Investment Managers
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- IGA Finance
- ADAP Health Care
- Exchange
- IGA Nasdaq
- ADAP Nasdaq
- Market Cap
- IGA 147.6M
- ADAP 158.6M
- IPO Year
- IGA N/A
- ADAP 2015
- Fundamental
- Price
- IGA $9.52
- ADAP $0.56
- Analyst Decision
- IGA
- ADAP Strong Buy
- Analyst Count
- IGA 0
- ADAP 4
- Target Price
- IGA N/A
- ADAP $2.79
- AVG Volume (30 Days)
- IGA 42.3K
- ADAP 2.2M
- Earning Date
- IGA 01-01-0001
- ADAP 03-05-2025
- Dividend Yield
- IGA 8.93%
- ADAP N/A
- EPS Growth
- IGA N/A
- ADAP N/A
- EPS
- IGA N/A
- ADAP N/A
- Revenue
- IGA N/A
- ADAP $175,041,000.00
- Revenue This Year
- IGA N/A
- ADAP $204.91
- Revenue Next Year
- IGA N/A
- ADAP N/A
- P/E Ratio
- IGA N/A
- ADAP N/A
- Revenue Growth
- IGA N/A
- ADAP 146.27
- 52 Week Low
- IGA $7.77
- ADAP $0.53
- 52 Week High
- IGA $8.88
- ADAP $2.05
- Technical
- Relative Strength Index (RSI)
- IGA 60.14
- ADAP 38.69
- Support Level
- IGA $9.11
- ADAP $0.55
- Resistance Level
- IGA $9.57
- ADAP $0.65
- Average True Range (ATR)
- IGA 0.13
- ADAP 0.05
- MACD
- IGA 0.04
- ADAP -0.00
- Stochastic Oscillator
- IGA 89.13
- ADAP 18.89
About IGA Voya Global Advantage and Premium Opportunity Fund of Beneficial Interest
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategy.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.